R Gray

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

C. Focan, S. M. Steinberg, M Blichert-Toft et al. · PubMed · 1998 · 2.2K citations

Medicine, Oncology, Pharmacotherapy +5

Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599

Alan B. Sandler, R Gray, Julie R. Brahmer et al. · Journal of Clinical Oncology · 2005 · 360 citations

Medicine, Oncology, Pharmacology +13

Postchemotherapy Adjuvant Tamoxifen Therapy Beyond Five Years in Patients With Lymph Node-Positive Breast Cancer

D. C. Tormey, R Gray, H. C. Falkson · JNCI Journal of the National Cancer Institute · 1996 · 202 citations

Medicine, Oncology, Breast Oncology +16

Tumor necrosis is a prognostic predictor for early recurrence and death in lymph node-positive breast cancer: a 10-year follow-up study of 728 Eastern Cooperative Oncology Group patients.

Kennedy W. Gilchrist, R Gray, Barbara Fowble et al. · Journal of Clinical Oncology · 1993 · 124 citations

Medicine, Oncology, Surgery +17

Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An eastern cooperative oncology group trial

D. C. Tormey, R Gray, Kennedy W. Gilchrist et al. · Cancer · 1990 · 73 citations

Medicine, Oncology, Pharmacotherapy +17